6vrp: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 16: Line 16:
</div>
</div>
<div class="pdbe-citations 6vrp" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 6vrp" style="background-color:#fffaf0;"></div>
==See Also==
*[[Antibody 3D structures|Antibody 3D structures]]
== References ==
== References ==
<references/>
<references/>

Revision as of 17:51, 17 June 2021

Reverse Transcriptase Diabody with R83T MutationReverse Transcriptase Diabody with R83T Mutation

Structural highlights

6vrp is a 2 chain structure with sequence from Human. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Ligands:,
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Publication Abstract from PubMed

This work presents a method for introducing synthetic symmetry into protein crystallization samples using an antibody fragment termed a diabody (Dab). These Dabs contain two target binding sites, and engineered disulfide bonds have been included to modulate Dab flexibility. The impacts of Dab engineering have been observed through assessment of thermal stability, small-angle X-ray scattering, and high-resolution crystal structures. Complexes between the engineered Dabs and HIV-1 reverse transcriptase (RT) bound to a high-affinity DNA aptamer were also generated to explore the capacity of engineered Dabs to enable the crystallization of bound target proteins. This strategy increased the crystallization hit frequency obtained for RT-aptamer, and the structure of a Dab-RT-aptamer complex was determined to 3.0-A resolution. Introduction of synthetic symmetry using a Dab could be a broadly applicable strategy, especially when monoclonal antibodies for a target have previously been identified.

Co-crystallization with diabodies: a case study for the introduction of synthetic symmetry.,Chesterman C, Arnold E Structure. 2021 Feb 23. pii: S0969-2126(21)00045-9. doi:, 10.1016/j.str.2021.02.001. PMID:33636101[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Chesterman C, Arnold E. Co-crystallization with diabodies: a case study for the introduction of synthetic symmetry. Structure. 2021 Feb 23. pii: S0969-2126(21)00045-9. doi:, 10.1016/j.str.2021.02.001. PMID:33636101 doi:http://dx.doi.org/10.1016/j.str.2021.02.001

6vrp, resolution 1.60Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA